Myriad Genetics Inc (MYGN) 20.65 $MYGN Downtrend Call

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 7:06 PM

Myriad Genetics Inc (MYGN) 20.65 $MYGN

Downtrend Call Working As Myriad Genetics Stock Falls 41.1% (MYGN)
Comtex SmarTrend(R) - Fri Sep 02, 12:52AM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 41.10% as of today's recent price of $20.44.
MYGN: 20.65 (+0.21)

Myriad Genetics Completes Acquisition of Assurex Health
GlobeNewswire - Thu Sep 01, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental health patients.
MYGN: 20.65 (+0.21)

Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference
GlobeNewswire - Tue Aug 30, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.
MYGN: 20.65 (+0.21), MS: 31.89 (-0.02)

Shares of MYGN Down 39.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 25, 1:06PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 39.68% as of today's recent price of $20.93.
MYGN: 20.65 (+0.21)

Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Wed Aug 24, 8:02AM CDT
LONDON, August 24, 2016 /PRNewswire/ --
JNJ: 119.32 (+0.24), ABT: 42.09 (-0.21), MYGN: 20.65 (+0.21), A: 47.00 (+0.01)

Weakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 6:59AM CDT
Myriad Genetics (MYGN) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
MYGN: 20.65 (+0.21), CBM: 43.27 (+0.10)

Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 7:38AM CDT
Myriad (MYGN) ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts.
MYGN: 20.65 (+0.21), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
Myriad Genetics, Inc. (MYGN) was a big mover last session, as the company saw its shares rise around 6% on the day.
MYGN: 20.65 (+0.21), ANIP: 59.86 (-1.56)

Downgrade Alert for Myriad Genetics (MYGN)
Comtex SmarTrend(R) - Thu Aug 11, 3:54AM CDT
Myriad Genetics (NASDAQ:MYGN) was downgraded from Buy to Hold at Gabelli & Co today. The stock closed yesterday at $19.70 on volume of 19.0 million shares, above average daily volume of 853,000. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
MYGN: 20.65 (+0.21)

Myriad Genetics Shares Down 43.1% Since SmarTrend's Sell Call (MYGN)
Comtex SmarTrend(R) - Wed Aug 10, 1:03PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 3 months, Myriad Genetics has returned 43.07% as of today's recent price of $19.75.
MYGN: 20.65 (+0.21)

Myriad Genetics (MYGN) Lags Q4 Earnings, New Tests Shine
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:44AM CDT
Myriad (MYGN) ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts.
BABY: 40.64 (+0.93), MYGN: 20.65 (+0.21), MASI: 59.90 (+0.47), IDXX: 114.09 (+0.93)

Myriad Genetics Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 09, 4:31PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $29.40 to a high of $30.39. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $29.86 on volume of 688,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 20.65 (+0.21)

Look for Shares of Myriad Genetics to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Aug 09, 4:29PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $29.40 to a high of $30.39. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $29.86 on volume of 688,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 20.65 (+0.21)

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:05PM CDT
-- Total Revenues of $186.5 Million
MYGN: 20.65 (+0.21)

What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:43AM CDT
Myriad's (MYGN) earnings outpaced the Zacks Consensus Estimate in all the past four quarters, with an average beat of 8.70%.
MYGN: 20.65 (+0.21), MDT: 87.32 (+0.34), INCY: 82.02 (+1.21), IONS: 29.46 (-0.58)

Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health
GlobeNewswire - Wed Aug 03, 3:17PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad's fiscal year 2016.
MYGN: 20.65 (+0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Opens New Café in Novato, CA

Another Feather in Paris Baguette’s Cap Alright, as far as pastry shops go, Paris Baguette is rolling out those cinnamon rolls like they're planting flags on the moon. They've just added a new café in Novato, California, bringing the artisanal charm of their iconic baked goods to yet another American doorstep. A Local Affair with Big Aspirations The man of the hour,...

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

Retirement Dreams Dashed: 61% Withdraw Early

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

$10,000 Boost Fuels Nichols College's Archaeological Quest

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

IM Cannabis's Third Quarter Financial Jolt

By Caleb Price Updated Nov 13, 2026 Category News Views 120

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Odessa Water Overbilling Lawsuit Surges Ahead

Full Steam Ahead for Odessa's Water Fight Odessa, a dust-blown Texas town, ain't giving up without a fight. The court just lit a fire under the efforts of 46,000 residents and businesses hollering about their water bills that seemed to skyrocket outta nowhere. This court ruling lets the class action against the City of Odessa and Performance Services—they're the folks...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Pine AI Unveils AI Studio & Real-World Call Feature

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...